Sign In
Buy CANF
$3.12
+0.0100 (+0.322%)
At Close: Jun 03, 2026
33 Stocks Moving in Thursday's Pre-Market Session
11:19am, Thursday, 16'th Apr 2020
Gainers
Soligenix, Inc (NASDAQ: SNGX) shares rose 95% to $2.73 in pre-market trading after the company reported an exclusive license deal for novel vaccine adjuvant from BTG...
Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
11:00am, Tuesday, 14'th Apr 2020
Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
Mid-Day Market Update: Dow Falls Over 500 Points; SCWorx Shares Spike Higher
04:25pm, Monday, 13'th Apr 2020
Midway through trading Monday, the Dow traded down 2.25% to 23185.53 while the NASDAQ fell 0.89% to 8,081.03. The S&P also fell, dropping 1.95% to 2,735.29.
The U.S. is the...
Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics
01:54pm, Monday, 13'th Apr 2020
As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and...
30 Stocks Moving in Monday's Pre-Market Session
10:56am, Monday, 13'th Apr 2020
Gainers
Biocept, Inc. (NASDAQ: BIOC) shares rose 68.3% to $0.5997 in pre-market trading. Biocept disclosed that it has verified a COVID-19 molecular diagnostic test.
U.S. Well...
Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
10:30am, Monday, 13'th Apr 2020
Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Mid-Afternoon Market Update: Crude Oil Up 2%; Biocept Shares Surge
12:00am, Monday, 13'th Apr 2020Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson
01:00pm, Tuesday, 07'th Apr 2020
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announce
Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
11:00am, Monday, 30'th Mar 2020
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced t
Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
12:00am, Monday, 30'th Mar 2020The Week In Cannabis: Marijuana Stocks Outperform S&P Again As Weed Is Deemed 'Essential' In COVID-19 Times
08:12pm, Saturday, 28'th Mar 2020
As the coronavirus (COVID-19) pandemic continues to spread, more and more states in the U.S. decide to declare cannabis an “essential” good, just like basic groceries...
Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update
11:00am, Friday, 27'th Mar 2020
Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update
